Safety, efficacy, and immunogenicity of the NVX-CoV2373 vaccine

Safety, efficacy, and immunogenicity of the NVX-CoV2373 vaccine

Introduction The coronavirus disease 2019 (COVID-19) pandemic, caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has resulted in significant morbidity and mortality worldwide. As SARS-CoV-2 moves into endemic status, vaccination remains a key element in protecting the health of...

Full description

Bibliographic Details
Main Authors:	Eddie Underwood, Lisa M. Dunkle, Shabir A. Madhi, Cynthia L. Gay, Paul T. Heath, Karen L. Kotloff, Katherine Smith, Gordon Chau, Shirley Galbiati, Alice McGarry, Wayne Woo, Iksung Cho, Katia Alves, Germán Áñez, Chijioke Bennett, Vivek Shinde, Louis Fries, Raburn M. Mallory, Gregory M. Glenn, Seth Toback
Format:	Article
Language:	English
Published:	Taylor & Francis Group 2023-12-01
Series:	Expert Review of Vaccines
Subjects:	clinical trial coronavirus covid-19, matrix-m adjuvant prevention protein-based vaccine sars-cov-2 vaccination nvx-cov2373
Online Access:	http://dx.doi.org/10.1080/14760584.2023.2218913

Similar Items

Safety and immunogenicity of SII-NVX-CoV2373 (COVID-19 vaccine) in adults in a phase 2/3, observer-blind, randomised, controlled studyResearch in context
by: Prasad S. Kulkarni, et al.
Published: (2023-03-01)

Pivoting to protein: the immunogenicity and safety of protein-based NVX-CoV2373 as a heterologous booster for inactivated and viral vector COVID-19 vaccines
by: Anthony M. Marchese, et al.
Published: (2023-12-01)

NVX-CoV2373 induces humoral and cellular immune responses that are functionally comparable to vector and mRNA-based vaccines
by: Franz Mai, et al.
Published: (2024-03-01)

Cytokine and Chemokine Production in Mice Inoculated with NVX-CoV2373 (Nuvaxovid<sup>®</sup>) in Comparison with Omicron BA.4/5 Bivalent BNT162b2 (Comirnaty<sup>®</sup>)
by: Tetsuo Nakayama, et al.
Published: (2023-11-01)

NVX-CoV2373-induced T- and B-cellular immunity in immunosuppressed people with multiple sclerosis that failed to respond to mRNA and viral vector SARS-CoV-2 vaccines
by: Magdalena Mueller-Enz, et al.
Published: (2023-07-01)

Biodistribution of the saponin-based adjuvant Matrix-M™ following intramuscular injection in mice
by: Cecilia Carnrot, et al.
Published: (2023-11-01)

Safety and Adverse Events Related to Inactivated COVID-19 Vaccines and Novavax; a Systematic Review
by: Omid Dadras, et al.
Published: (2022-07-01)

Myopericarditis following both BNT162b2 and NVX-CoV2373
by: Saima Ahmad, et al.
Published: (2022-12-01)

Novavax NVX-COV2373 triggers neutralization of Omicron sub-lineages
by: Jinal N. Bhiman, et al.
Published: (2023-01-01)

Safety and efficacy of NVX-CoV2373 Covid-19 vaccine
by: Heath, PT, et al.
Published: (2021)

Fab and Fc contribute to maximal protection against SARS-CoV-2 following NVX-CoV2373 subunit vaccine with Matrix-M vaccination
by: Matthew J. Gorman, et al.
Published: (2021-09-01)

Protein vaccine NVX-CoV2373 elicits functional T cell immunity
by: Pengcheng Zhou
Published: (2022-10-01)

Safety, immunogenicity, and efficacy of a COVID-19 vaccine (NVX-CoV2373) co-administered with seasonal influenza vaccines
by: Toback, S, et al.
Published: (2021)

Different dose regimens of a SARS-CoV-2 recombinant spike protein vaccine (NVX-CoV2373) in younger and older adults: A phase 2 randomized placebo-controlled trial.
by: Neil Formica, et al.
Published: (2021-10-01)

A multiresolution methodology for signal-level fusion and data assimilation with applications to remote sensing
Published: (2003)

Immunogenicity of NVX-CoV2373 heterologous boost against SARS-CoV-2 variants
by: Kirsten E. Lyke, et al.
Published: (2023-07-01)

Angioedema‐like eyelid edema following the second NVX‐CoV2373 COVID‐19 vaccination
by: Mari Matsumoto, et al.
Published: (2023-10-01)

SARS-CoV-2 spike glycoprotein vaccine candidate NVX-CoV2373 immunogenicity in baboons and protection in mice
by: Jing-Hui Tian, et al.
Published: (2021-01-01)

Safety and efficacy of the NVX-CoV2373 coronavirus disease 2019 vaccine at completion of the placebo-controlled phase of a randomized controlled trial
by: Heath, PT, et al.
Published: (2022)

NVX-CoV2373 vaccination induces functional SARS-CoV-2–specific CD4+ and CD8+ T cell responses
by: Carolyn Rydyznski Moderbacher, et al.
Published: (2022-10-01)

Thromboses of major arteries and ChAdOx1 nCov-19 vaccination
by: Rujittika Mungmunpuntipantip, et al.
Published: (2021-11-01)

“They have produced a vaccine, but we doubt if COVID-19 exists”: correlates of COVID-19 vaccine acceptability among adults in Kano, Nigeria
by: Zubairu Iliyasu, et al.
Published: (2021-11-01)

Analysis of cases of reinfection of past SARS-CoV-2 patients in Pudong New Area of Shanghai
by: ZHANG Ge, et al.
Published: (2024-02-01)

CORONAVIRUS VACCINE DEVELOPMENT: FROM SARS AND MERS TO COVID-19 (RUSSIAN TRANSLATION)
by: Y.‑D. Li, et al.
Published: (2020-12-01)

Vaccination Confidence among Healthcare Workers: Results from Two Anamnestic Questionnaires Adopted in the COVID-19 and Influenza Campaign
by: Ihab Mansour, et al.
Published: (2022-10-01)

SARS-CoV-2 Omicron Symptomatic Infections in Previously Infected or Vaccinated South African Healthcare Workers
by: Marta C. Nunes, et al.
Published: (2022-03-01)

Acceptance and concerns regarding COVID-19 vaccination in Kerala, India
by: Anamika Anil, et al.
Published: (2021-09-01)

Safety, Tolerability, and Immunogenicity of Booster Dose with MVC-COV1901 or MVC-COV1901-Beta SARS-CoV-2 Vaccine in Adults: A Phase I, Prospective, Randomized, Open-Labeled Study
by: Chia En Lien, et al.
Published: (2023-12-01)

A Qualitative Study Exploring Motivators and Barriers to COVID-19 Vaccine Uptake among Adults in South Africa and Zimbabwe
by: Nellie Myburgh, et al.
Published: (2023-03-01)

Generation of efficacy data on 60 years and older population using SARS-CoV-2 vaccines
by: Prasanta Kumar Ghosh
Published: (2021-01-01)

Vaccination against SARS-CoV-2 Does Not Protect against the Development of Anosmia in a Hamster Model
by: Rachel A. Reyna, et al.
Published: (2023-10-01)

Side Effects and Perceptions Following COVID-19 Vaccination in Jordan: A Randomized, Cross-Sectional Study Implementing Machine Learning for Predicting Severity of Side Effects
by: Ma’mon M. Hatmal, et al.
Published: (2021-05-01)

Social Response to the Vaccine against COVID-19: The Underrated Power of Influence
by: Dimitra S. Mouliou, et al.
Published: (2021-12-01)

COVID-19 vaccine hesitancy – reasons and solutions to achieve a successful global vaccination campaign to tackle the ongoing pandemic
by: Kuldeep Dhama, et al.
Published: (2021-10-01)

Current data on Covid-19 vaccine in pediatrics
by: Lalitphat Treerattanapun, et al.
Published: (2022-01-01)

Coronavirus vaccine development: from SARS and MERS to COVID-19
by: Yen-Der Li, et al.
Published: (2020-12-01)

Transient akathisia after the SARS-Cov-2 vaccine
by: Meagen R. Salinas, et al.
Published: (2021-01-01)

Evaluating risk factors associated with COVID-19 infections among vaccinated people early in the U.S. vaccination campaign: an observational study of five states, January–March 2021
by: Katrin S. Sadigh, et al.
Published: (2022-09-01)

Identification of SARS-CoV-2 Vaccine Epitopes Predicted to Induce Long-Term Population-Scale Immunity
by: Mark Yarmarkovich, et al.
Published: (2020-06-01)

Heterologous vaccination of BNT162b2 in Ad26. COV2.S-vaccinated healthcare workers elicits long-term humoral immune response
by: B Jacobson, et al.
Published: (2022-09-01)